CPC A61K 38/37 (2013.01) [A61K 39/12 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 48/0008 (2013.01); A61K 48/0075 (2013.01); C07K 14/755 (2013.01); C12N 7/00 (2013.01); G01N 33/6854 (2013.01); C12N 2710/16044 (2013.01); C12N 2750/14121 (2013.01); C12N 2750/14141 (2013.01); C12N 2750/14143 (2013.01); G01N 2333/015 (2013.01)] | 6 Claims |
1. A pharmaceutical formulation comprising a recombinant AAV FVIII virus, sodium phosphate at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml, mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml, and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml.
|